Adverse Outcome Pathways
An adverse outcome pathway (AOP) is structured representation of biological events leading to adverse effects and is considered relevant to risk assessment. The AOP links in a linear way existing knowledge along one or more series of causally connected key events (KE) between two points — a molecular initiating event (MIE) and an adverse outcome (AO) that occur at a level of biological organization relevant to risk assessment. The linkage between the events is described by key event relationships (KER) that describe the causal relationships between the key events. AOPs are important for expanding the use of mechanistic toxicological data for risk assessment and regulatory applications.
- Enzymes
- Anti-Platelet Drugs
- Aspirin
Related Conference of Adverse Outcome Pathways
19th International Conference on Human Genomics and Genomic Medicine
22nd World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
17th International Conference on Human Genetics and Genetic Diseases
Adverse Outcome Pathways Conference Speakers
Recommended Sessions
- Adverse Outcome Pathways
- Biomarkers in Toxicogenomics
- Cardiovascular Toxicology
- Concept of Toxicogenomics
- Drug monitoring
- Genetic Toxicology
- Genomic Approaches to Predictive Toxicology
- Predictive Human Toxicity and ADME/Tox Studies
- Reproductive and Developmental Toxicology
- Technologies in Toxicogenomics
- Toxicogenomics
- Toxicology study in Haemostasis
- Toxicopathology
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Advanced Imaging and Single-Cell Technologies - cellscience-cs-2027 (UK)
- Animal Genetics - Genome 2027 (Germany)
- Artificial Intelligence in Cell and Molecular Research - cellscience-cs-2027 (UK)
- Bioinformatics and Computational Biology - cellscience-cs-2027 (UK)
- Bioinformatics and Computational Biology - Genome 2027 (Germany)
- Biomarkers and Microarrays - Genome 2027 (Germany)
- Biotechnology and Molecular Therapeutics - cellscience-cs-2027 (UK)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Cell Biology and Molecular Oncology - cellscience-cs-2027 (UK)
- Cancer Genomics - Genome 2027 (Germany)
- Cell Biology and Cellular Mechanisms - cellscience-cs-2027 (UK)
- Cellular Metabolism and Metabolic Biology - cellscience-cs-2027 (UK)
- Cellular signaling and Signal Transduction - cellscience-cs-2027 (UK)
- Clinical genomics - Genome 2027 (Germany)
- Comparative Genomics - Genome 2027 (Germany)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Emerging Technologies and Future Directions in Cell Science - cellscience-cs-2027 (UK)
- Epigenomics and Epigenetics - Genome 2027 (Germany)
- Functional Genomics - Genome 2027 (Germany)
- Gene Editing and Genetic Engineering - Genome 2027 (Germany)
- Genetic Disorder - Genome 2027 (Germany)
- Genetics, Genomics and Genome Biology - cellscience-cs-2027 (UK)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Genomic Instability - Genome 2027 (Germany)
- Genomic Medicine - Genome 2027 (Germany)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Immunology and Cellular Immunity - cellscience-cs-2027 (UK)
- Microbial Genomics - Genome 2027 (Germany)
- Molecular Biology and Gene Regulation - cellscience-cs-2027 (UK)
- Molecular Diagnostics and Biomarkers - cellscience-cs-2027 (UK)
- Molecular Medicine and Translational Research - cellscience-cs-2027 (UK)
- Molecular Microbiology and Host–Pathogen Interactions - cellscience-cs-2027 (UK)
- Next generation sequencing - Genome 2027 (Germany)
- Nutrigenomics - Genome 2027 (Germany)
- Personalized and Regenerative Medicine - Genome 2027 (Germany)
- Pharmacogenomics - Genome 2027 (Germany)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Plant Genomics and Molecular Pharming - Genome 2027 (Germany)
- Stem Cell Biology and Regenerative Medicine - cellscience-cs-2027 (UK)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Structural Genomics - Genome 2027 (Germany)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)
- Trends in Genomics and Pharmacogenomics - Genome 2027 (Germany)

